Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 7884.016 | 0.5363 | -0.4834 | 0.4603 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7884.016 | 0.3579 | -0.7855 | 0.4603 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 7884.016 | 0.2138 | -0.9300 | 0.4603 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7885.016 | 0.8743 | 0.6568 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7885.016 | 0.9769 | 0.9355 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7885.016 | 0.9060 | 0.7417 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7885.016 | 0.9259 | 0.7956 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7885.016 | 0.9899 | 0.9717 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 7885.016 | 0.7915 | 0.4414 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 7885.016 | 0.4439 | -0.3590 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7885.016 | 0.3019 | -0.6265 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 7885.016 | 0.2068 | -0.7802 | 0.7137 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7886.016 | 1.0664 | 1.1870 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7886.016 | 0.9522 | 0.8684 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7886.016 | 0.9872 | 0.9645 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7886.016 | 1.0006 | 1.0017 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7886.016 | 0.9163 | 0.7712 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 7886.016 | 0.7043 | 0.2286 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 7886.016 | 0.4215 | -0.3981 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7886.016 | 0.2128 | -0.7672 | 0.7194 | |
MDA-MB-175-VII | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 7886.016 | 0.0696 | -0.9508 | 0.7194 | |
MDA-MB-231 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7892.016 | 0.9996 | 0.9997 | 2.3475 | |
MDA-MB-231 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7892.016 | 0.9279 | 0.9372 | 2.3475 | |
MDA-MB-231 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7892.016 | 0.9847 | 0.9869 | 2.3475 | |
MDA-MB-231 | TNBC | Basal B | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7892.016 | 1.0178 | 1.0151 | 2.3475 |